Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II a, Double-Blind, Randomised, Group Sequential Adaptive Assignment Design Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Seven Fixed Doses of Intravenous BIBN 4096 BS Ranging From 0.1 to 10.0 mg Versus Placebo in the Treatment of a Single Attach of Acute Migraine Headache

NCT02198339 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02198339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02198339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II a, Double-Blind, Randomised, Group Sequential Adaptive Assignment Design Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Seven Fixed Doses of Intravenous BIBN 4096 BS Ranging From 0.1 to 10.0 mg Versus Placebo in the Treatment of a Single Attach of Acute Migraine Headache
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
February 28, 1999
Completion date
Not reported
Enrollment
126 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

migraine disorders